Ogeda S.A.

The top 11 Japanese pharmaceutical firms have relatively higher R&D success rates in the US market in the areas of oncology and central nervous system (CNS), a new report from Citeline's Biomedtracke

Two new venture capital funds were announced a day apart during the last week of June, each with $200m to fund early-stage biotechnology companies, though only one is exclusively focused on drug devel

Sentiments around the 2023 biopharma dealmaking environment may be mixed, but Mike Luther, the global head of search and evaluation business development at Astellas Pharma, Inc. , hopes the coming ye

Astellas Pharma, Inc. relies heavily on Xtandi (enzalutamide), the prostate cancer drug it commercializes in the US with Pfizer Inc. and the company's top revenue generator. While Xtandi still has